Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.

JAMASep 22, 2026
Clinical ResearchOncology (Medical)Open access

Rodney J Ellis, Stephanie L Pugh, James B Yu et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase-3 randomized clinical trial compared stereotactic body radiotherapy (SBRT) to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) in patients with localized intermediate-risk prostate cancer. Among 698 participants, SBRT showed fewer bowel-related minimal clinically important declines (34.9% vs 43.8%, P = .03) but did not demonstrate superior disease-free survival (DFS) at 3 years (88.6% for SBRT vs 92.1% for MH-IMRT, P < .001).

Key findings

  • Fewer grade 3 + 4 genitourinary adverse events occurred in the SBRT group (0.6% vs 2.5%, P = .04).
  • At 2 years, no significant difference in urinary irritative domain (35.4% vs 33.7%, P = .68).
  • SBRT resulted in significantly fewer MCIDs in the bowel domain (34.9% vs 43.8%, P = .03).
  • At 3 years, DFS was 88.6% for SBRT vs 92.1% for MH-IMRT (P < .001).

Why it matters

Understanding the comparative effectiveness of SBRT and MH-IMRT is crucial for optimizing treatment strategies in localized prostate cancer, particularly regarding quality of life and disease control.

Source

PubMed · PMID 42593775Free full text on PubMed Central

Published in JAMA. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.